Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
about
Non-natural and photo-reactive amino acids as biochemical probes of immune functionRecognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytesActive specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trialsAn analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptidesCancer immunotherapy targeting Wilms' tumor gene WT1 product.Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer.Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory RegimenDetermination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study.Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.Vaccines as consolidation therapy for myeloid leukemia.Analogue peptides for the immunotherapy of human acute myeloid leukemia.A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue.Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes.Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine.Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome.WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.WT1 Mutation in Childhood Cancer.Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children.WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ.Wilms' tumour gene 1 (WT1) in human neoplasia.Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies.Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors.WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval.DNA sequencing-based HLA typing detects a B-cell ALL blast-specific mutation in HLA-A(*)2402 resulting in loss of HLA allele expression.Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer.Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination
P2860
Q21144124-60DFDB4A-3698-4148-B80C-FFC63592E1C8Q24672952-B461B938-7551-4DCD-B65C-27BBDEEC420EQ27026836-685D1D1D-278F-4512-BE28-7C90C477FEC5Q34862104-EDD55456-42C8-4BA6-BA93-A5330BA7C172Q35538449-7ECA36E5-05ED-4B3C-99D1-92E975462A5DQ36198150-46137B33-B31D-4D81-8B46-F9A63242B6A3Q36238704-B2B5C8C4-E2CD-4953-A097-B11F4F97E8FEQ36409532-5054E605-DE21-4882-B5DD-85852D01A568Q37148167-A2467944-637B-4205-B912-43C6E52016E1Q37320454-EEF2F8EA-06DF-4A5C-AD19-8758D8195E61Q37535549-5A2E0251-BA66-4473-83C1-AB9FB266CECFQ37731720-D76770ED-7F90-40A0-8EA5-583F1125245AQ37842342-366DC5AB-1255-4DA5-948E-C6E3795E0EADQ38599586-3AC8D631-E663-4F52-BAF9-DA63E4141CE7Q38714821-5B615C96-EA21-42F3-AA42-DAA6CB4B365DQ39886839-AD50A1CD-1C82-415D-807A-8EE6953A7896Q39990744-96FF1EBC-8AEA-4343-A394-2492FF7FA270Q40228775-ABA2E901-F341-46BA-847F-FECD3C04764AQ42050372-0B8BE5BB-9FB5-478E-9C7C-9C2C4169EC35Q42693220-26BB4730-68AA-4E24-B0E5-2FAC0EF36E5BQ44805701-B19C0B23-5B76-496B-87B9-407454C3E4FDQ48280437-5AB514A3-1118-4342-8F5C-516A80C2D15CQ50498738-537F419E-C310-44B7-B561-C876DD44DEB6Q51490182-25EA7FDB-B708-4398-A9E6-BF18F7EC0BDFQ51583305-09E21EED-96A7-402A-B628-E21E6016B86AQ51830253-39F1CBFE-685C-480B-8D5C-0F0D8D186CDFQ51887293-385F7C2D-C358-4709-A5E7-860FDCF0B2D8Q52938297-C100515F-12F5-4242-8E0D-D6298B0F3E79Q52969773-AAA89E50-90B8-4A1A-8F01-7B66DAAF3018Q53092142-D17D1CF7-DDB8-4584-9D60-1FF7882A3A31Q53345813-199D2485-9599-49D6-8D0C-FB86CCF401B3Q53375290-768002A1-5B2E-4F2D-B82F-3C1318F60396Q55367086-A9F630B4-0108-4C43-A042-9E7C0F99B04EQ58742957-C1F84B9F-4EF0-4EC8-8732-03E602F74594
P2860
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Enhanced induction of human WT ...... t HLA-A*2402-binding residues.
@en
Enhanced induction of human WT ...... t HLA-A*2402-binding residues.
@nl
type
label
Enhanced induction of human WT ...... t HLA-A*2402-binding residues.
@en
Enhanced induction of human WT ...... t HLA-A*2402-binding residues.
@nl
prefLabel
Enhanced induction of human WT ...... t HLA-A*2402-binding residues.
@en
Enhanced induction of human WT ...... t HLA-A*2402-binding residues.
@nl
P2093
P1476
Enhanced induction of human WT ...... t HLA-A*2402-binding residues.
@en
P2093
Akihiro Tsuboi
Akiko Nakano
Akio Hiraki
Haruo Sugiyama
Hiroko Nakajima
Hiroyasu Ogawa
Ichiro Kawase
Keiko Udaka
Manabu Kawakami
P2888
P304
P356
10.1007/S00262-002-0328-9
P577
2002-10-18T00:00:00Z